{"id":766540,"date":"2023-06-28T02:03:14","date_gmt":"2023-06-28T06:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-announces-publication-of-phase-3-enhance-data-in-the-american-journal-of-respiratory-and-critical-care-medicine\/"},"modified":"2023-06-28T02:03:14","modified_gmt":"2023-06-28T06:03:14","slug":"verona-pharma-announces-publication-of-phase-3-enhance-data-in-the-american-journal-of-respiratory-and-critical-care-medicine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-announces-publication-of-phase-3-enhance-data-in-the-american-journal-of-respiratory-and-critical-care-medicine\/","title":{"rendered":"Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine"},"content":{"rendered":"

\nEnsifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal
\n<\/h2>\n
\n

LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), announces the American Journal of Respiratory and Critical Care Medicine (\u201cAJRCCM\u201d)<\/em> has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease (\u201cCOPD\u201d).<\/p>\n

The publication reports results from Verona Pharma\u2019s successful ENHANCE trials demonstrating improvements with ensifentrine in lung function, symptoms and quality of life measures, as well as a substantial reduction in the rate and risk of COPD exacerbations and a favourable safety profile. The manuscript, entitled \u2018Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)\u2019, is available online here<\/a> and will be published in an upcoming issue of AJRCCM.<\/em> It follows announcements of top-line data from the ENHANCE-1 and ENHANCE-2 trials in December<\/a> and August<\/a> 2022, respectively.<\/p>\n

Data from the ENHANCE program formed the basis of Verona Pharma\u2019s New Drug Application (\u201cNDA\u201d), which was submitted in June 2023 to the US Food and Drug Administration (\u201cFDA\u201d) for the approval of ensifentrine for the maintenance treatment of patients with COPD.<\/p>\n

Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4, combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule. If approved, it is expected to be the first novel mechanism available for the treatment of COPD in more than 10 years.<\/p>\n

\u201cDespite available treatment regimens, millions of patients with COPD continue to struggle with debilitating, uncontrolled symptoms from this progressive condition and physicians are looking to novel treatment options to improve patient outcomes,\u201d said Antonio Anzueto, MD, Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System. \u201cThe ENHANCE trials demonstrate ensifentrine\u2019s outstanding ability to reduce the rate and risk of COPD exacerbations and to provide meaningful improvements in lung function and symptoms in a broad COPD population. I believe ensifentrine, with its novel bronchodilator and non-steroidal anti-inflammatory activity, has the potential to change the treatment paradigm for COPD patients.\u201d<\/p>\n

\n About the ENHANCE program<\/strong>\n <\/p>\n

The two randomized, double-blind, placebo-controlled trials (ENHANCE-1 and ENHANCE-2) evaluated the efficacy and safety of nebulized ensifentrine as monotherapy and added onto a single bronchodilator, either a LAMA or a LABA, compared to placebo, and approximately 20% of subjects received inhaled corticosteroids with their long-acting bronchodilator. The two trials replicated measurements of efficacy and safety data over 24 weeks and ENHANCE-1 also evaluated long-term safety and exacerbations over 48 weeks.<\/p>\n